Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 12:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Warfarin plus Aspirin Clear all

Conditions: Aortic Valve Disorder
Interventions: SAVR Warfarin, SAVR Aspirin, TAVR Warfarin and clopidogrel, TAVR Aspirin and clopidogrel; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Heart Failure
Interventions: Warfarin titrated to an INR of 2.5-3.0, Aspirin, Clopidogrel 75; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 1,587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 79
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more

Conditions: Myeloma
Interventions: Bendamustine, Lenalidomide, Dexamethasone, Aspirin, Prophylaxis, Antibiotic, Biweekly Follow Up, Cyclical Follow Up, Restaging, Post-Treatment Follow Up; Drug · Other
Lead sponsor: Robert Redner, MD; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 22
States / cities: Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more

Conditions: Pulmonary Embolism, Venous Thrombosis
Interventions: Enteric Coated Aspirin, Warfarin, Rivaroxaban; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 18,883 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 30
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more

Conditions: Multiple Myeloma, Plasma Cell Neoplasm
Interventions: Lenalidomide, Dexamethasone, Anticoagulants; Drug
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 16
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 13 more

Conditions: Non-Valvular Atrial Fibrillation, Left Atrial Appendage Closure
Interventions: Edoxaban, WATCHMAN LAA Closure, Aspirin and Clopidogrel, Aspirin and Warfarin; Drug · Device
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Ischemic Stroke, Patent Foramen Ovale
Interventions: Warfarin, Aspirin; Drug
Lead sponsor: Columbia University; Other
Eligibility: 30 Years to 85 Years
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoarthritis of the Knee, Coagulopathy
Interventions: Pennsaid; Drug
Lead sponsor: Nathan Wei, MD, FACP, FACR:; Other
Eligibility: 55 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Frederick, Maryland

Conditions: Atrial Fibrillation
Interventions: dabigatran with ASA, warfarin, dabigatran without ASA; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 14
States / cities: Fayetteville, Arkansas • La Mesa, California • Pensacola, Florida + 11 more

Conditions: Cardiac Disease
Interventions: Not listed
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Bleeding, Clot Blood
Interventions: Aspirin, Warfarin; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Chicago, Illinois • New York, New York • Houston, Texas

Conditions: Upper Gastrointestinal Bleeding, Peptic Ulcer Hemorrhage, Anticoagulant-induced Bleeding
Interventions: Clinician Notification with Nurse Facilitation (CNNF), Wait list control; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Acute Decompensated Heart Failure, Sleep Disordered Breathing
Interventions: MV ASV, Optimized Medical Treatment; Device · Drug
Lead sponsor: ResMed; Industry
Eligibility: 21 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 14
States / cities: Huntsville, Alabama • Los Angeles, California • Denver, Colorado + 11 more

Conditions: Atrial Fibrillation, Percutaneous Coronary Intervention
Interventions: Dabigatran Etexilate 110mg, Warfarin 3mg, Aspirin, Dabigatran Etexilate 150mg, Clopidogrel or Ticagrelor, Warfarin 5mg, Warfarin 1mg; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 2,725 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 45
States / cities: Birmingham, Alabama • Cottonwood, Arizona • Mesa, Arizona + 41 more

Conditions: Cryptogenic Stroke
Interventions: AMPLATZER PFO Occluder, Standard of Care - Medical Management; Device · Other
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 980 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 61
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 52 more

Conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: bortezomib, lenalidomide, dexamethasone; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 275
States / cities: Scottsdale, Arizona • Fairfield, California • San Diego, California + 184 more

Conditions: Aortic Stenosis
Interventions: TAVR, Warfarin plus Aspirin, Aspirin Only; Device · Other
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: Not listed
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 7
States / cities: San Diego, California • Washington D.C., District of Columbia • Ridgewood, New Jersey + 4 more

Conditions: Patent Foramen Ovale, Stroke, Ischemic Attack, Transient
Interventions: STARFlex septal closure system, Best medical therapy; Device · Drug
Lead sponsor: NMT Medical; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Frequency of Reduced Leaflet Motion After Surgical Aortic Valve Replacement and Transcatheter Aortic Valve Replacement.

Warfarin and Antiplatelet Therapy in Chronic Heart Failure

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure

Patent Foramen Ovale in Cryptogenic Stroke Study

Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants

PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin

Triple Antithrombotic Therapy in Cardiac Patients Requiring Revascularization

Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device

Anticoagulation With Enhanced Gastrointestinal Safety

Cardiovascular Improvements With MV ASV Therapy in Heart Failure

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Patent Foramen Ovale Closure or Medical Therapy After Stroke - RESPECT Trial

Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

Strategies to Prevent Transcatheter Heart Valve Dysfunction in Low Risk Transcatheter Aortic Valve Replacement

Evaluation of the STARFlex® Septal Closure System in Patients With a Stroke or TIA Due to the Possible Passage of a Clot of Unknown Origin Through a Patent Foramen Ovale (PFO)